Showing results (1-10 of 28) with videos related to
Sort By:
Pageof 3
Current Drug Targets|March 17, 2012
Linagliptin: a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitorRitesh Agrawal, Pratima Jain, S N DikshitCurrent Drug Targets|January 19, 2012
Apixaban: a new player in the anticoagulant classRitesh Agrawal, Pratima Jain, S N DikshitCombinatorial Chemistry & High Throughput Screening|November 13, 2012
Ligand-based pharmacophore detection, screening of potential gliptins and docking studies to get effective antidiabetic agentsRitesh Agrawal, Pratima Jain, Subodh Narayan DikshitProtein and Peptide Letters|April 24, 2013
3D QSAR and docking studies of various amido and benzyl-substituted 3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl analogs as DPP-IV inhibitorsRitesh Agrawal, Pratima Jain, Subodh Narayan Dikshit, et al.Combinatorial Chemistry & High Throughput Screening|January 12, 2013
3D QSAR and docking study of gliptin derivatives as DPP-IV inhibitorsRitesh Agrawal, Pratima Jain, Subodh Narayan Dikshit, et al.Mini Reviews in Medicinal Chemistry|April 20, 2012
Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptinRitesh Agrawal, Radhe Shyam Bahare, Pratima Jain, et al.Current Drug Targets|August 3, 2013
The first approved agent in the Glitazar's Class: SaroglitazarRitesh AgrawalRecent Patents on Anti-Cancer Drug Discovery|May 22, 2014
Next generation tyrosine kinase inhibitor (TKI): afatinibSuresh Kumar, Ritesh AgrawalPeerj. Computer Science|January 3, 2022
Frameworks for developing an Agro-Prosumer Community Group platformPratima Jain, Vidyasagr PotdarRNA (New York, N.Y.)|April 21, 2005
Editing efficiency of a Drosophila gene correlates with a distant splice site selectionRitesh Agrawal, Gary D StormoPageof 3